In this sense, phosphorylated-tau 181 (p-tau181) assessed in plasma was the first p-tau specie to demonstrate good accuracy for discriminating subjects with AD versus controls [[7], [8], [9], [10]] and has been widely used by researchers in recent years [11,12]. The gene discussed is MAPT; the disease is Alzheimer disease.